Global Exosome-Based Therapy Market Size to Hit USD 288.10 Million by 2035 – SNS Insider
Global Exosome-Based Therapy Market Growth is Driven by Growing Clinical Research Activity, Advancements in Exosome Engineering, and Increasing Adoption of Cell-Free Therapeutic Platforms.
Austin, United States, May 07, 2026 (GLOBE NEWSWIRE) — According to SNS Insider, the Exosome-Based Therapy Market was valued at USD 54.08 million in 2025 and is expected to reach USD 288.10 million by 2035, growing at a CAGR of 18.22% during the forecast period of 2026-2035. The market for exosome-based therapy is a growing area of sophisticated biologics that are intended to transmit and utilize extracellular vesicles’ therapeutic effects in life-saving regenerative medicine.
Exosome-Based Therapy Market Size & Forecast
- Market Size (2025): USD 54.08 Million
- Projected Market Size (2035): USD 288.10 Million
- CAGR (2026–2035): 18.22%
- Forecast Period: 2026–2035
- Base Year: 2025
Get a Sample Report of Exosome-Based Therapy Market: https://www.snsinsider.com/sample-request/9777
The U.S. Exosome-Based Therapy Market is projected to grow from USD 19.51 Million in 2025 to USD 87.64 Million by 2035, at a CAGR of 16.22%. The market is expanding due to an increase in clinical research, the use of cell-free regenerative therapies, developments in exosome engineering, and the expansion of applications in neurological illnesses and oncology.
Major Exosome-Based Therapy Market Companies Listed in the Report are
- Codiak BioSciences
- Evox Therapeutics
- Capricor Therapeutics
- Exopharm
- Aegle Therapeutics
- ThermoGenesis / Thermo Fisher Scientific
- ReNeuron
- Kimera Labs
- Vesigen Therapeutics
- Eternal Labs
- ExoCoBio
- Anjarium Biosciences
- Avidity Biosciences
- PureTech Health
- Celularity
- Exogenus Therapeutics
- Aruna Bio
- Evoxplore Therapeutics
- Hansa Biopharma
- Exostem Bio
Rising Demand for Cell-Free Therapeutic Platforms Globally
The market for exosome-based therapeutics is driven by the increasing demand for cell-free treatments. Exosome-based therapy offers several advantages over conventional cell therapy, including less immunological rejection, reduced security risk, and improved biological stability. They are highly appropriate for therapeutic delivery for regenerative medicine and targeted medication administration because of their innate tendency to distribute proteins, RNA, or other biological molecules. Exosome platforms are therefore being included into core therapeutic innovations by nearly 60% of active developers, accelerating clinical research and technological uptake.
Segmentation Analysis:
By Source
In 2025, Mesenchymal Stem Cell (MSC) dominated with 45% share due to their well-established therapeutic potential, broad clinical research applications, and proven regenerative capabilities. The immune cell type is the most rapidly growing sub-segment, owing to rising number of studies on immunotherapy and oncology.
By Therapeutic Application
In 2025, Oncology dominated with 38% share due to high requirement of new cancer medications and capable of transporting drug/gene therapy. Neurological diseases, is also the fastest growing market on account of high unmet needs in CNS therapeutics and regenerative medicine.
By Technology
In 2025, Native Exosomes dominated with 42% share due to simpler manufacturing, proven safety profiles, and widespread use in preclinical and clinical studies. Modified exosomes represent the most rapidly growing due to advancements in targeted delivery and RNA/protein cargo loading.
By End User
In 2025, Pharmaceutical and Biotechnology Companies dominated with 50% share as it has invested massively in R&D, clinical trials and proprietary exosome platforms. Hospitals and specialized clinics are the fastest growing and are increasingly involved in early access program globally.
Do you have any specific queries or need any customization research on Exosome-Based Therapy Market, make an Enquiry Now: https://www.snsinsider.com/enquiry/9777
Exosome-Based Therapy Market Key Segments
By Source
- Mesenchymal stem cell (MSC)
- Dendritic cell
- Immune cell
By Therapeutic Application
- Oncology
- Neurological disorders
- Cardiovascular diseases
- Inflammatory and autoimmune disorders
- Regenerative medicine
By Technology
- Native exosomes
- Modified exosomes
- Exosome mimetics or synthetic vesicles
By End User
- Pharmaceutical and biotechnology companies
- Research and academic institutes
- Hospitals and specialized clinics
Regional Insights:
With 44% of the worldwide market share, North America leads the exosome-based therapeutic industry. A thriving biotechnology ecosystem, clinical research volume, R&D investment, and early adopters of cutting-edge exosome therapies for cancer, regenerative medicine, and other purposes are the region’s main advantages.
The market for exosome-based therapy is growing at the fastest rate in Asia-Pacific, with a compound annual growth rate (CAGR) of about 23.31%. Increased funding for regenerative medicine, a boom in clinical research, and the wider use of cutting-edge biologic treatments are the main drivers of this rapid expansion.
Recent Developments:
- In March 2025: Codiak BioSciences announced the advancement of its exoIL-12 program into Phase II clinical trials for oncology, highlighting the therapeutic potential of engineered exosomes in cancer immunotherapy.
- In February 2025: Evox Therapeutics reported positive preclinical results for its engineered exosome platform delivering RNA therapeutics to the central nervous system, advancing its neurodegenerative disease pipeline.
Exclusive Sections of the Report (The USPs):
- EXOSOME THERAPY ADOPTION & DEPLOYMENT METRICS – helps you understand enterprise adoption trends, therapeutic application growth, and the increasing number of developers entering the exosome-based therapy landscape.
- PLATFORM TECHNOLOGY & DELIVERY INNOVATION ANALYSIS – helps you track adoption of native, modified, and exosome mimetic platforms along with advancements in targeted RNA/protein payload delivery systems.
- CLINICAL DEVELOPMENT & COMMERCIALIZATION INSIGHTS – helps you evaluate adoption trends across different clinical development stages and identify commercialization opportunities for advanced exosome therapies.
- THERAPEUTIC PERFORMANCE & REGULATORY COMPLIANCE METRICS – helps you assess efficacy improvements, regenerative outcomes, GMP compliance, and adherence to FDA/EMA regulatory standards.
- R&D COST OPTIMIZATION & ENTERPRISE VALUE ANALYSIS – helps you understand manufacturing cost impact, ROI realization, enterprise retention trends, and value creation from customized exosome programs.
- COMPETITIVE LANDSCAPE & STRATEGIC POSITIONING – helps you gauge the competitive strength of key exosome therapy developers based on platform innovation, clinical pipeline expansion, partnerships, and therapeutic capabilities.
Buy an Enterprise-User PDF of Exosome-Based Therapy Market Outlook Report 2026-2035: https://www.snsinsider.com/checkout/9777
Exosome-Based Therapy Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 54.08 Million |
| Market Size by 2035 | USD 288.10 Million |
| CAGR | CAGR of 18.22% From 2026 to 2035 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Historical Data | 2022-2024 |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Related Market Reports
Exosome Diagnostics And Therapeutics Market
Cell and Gene Therapy CDMO Market
Cell & Gene Therapy Manufacturing Services Market
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315-961-9094 (US) Email: info@snsinsider.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.
